469 related articles for article (PubMed ID: 28300856)
1. Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
Grove G; Zerweck C; Houser T; Andrasfay A; Gauthier B; Holland C; Piacquadio D
J Drugs Dermatol; 2017 Feb; 16(2):140-144. PubMed ID: 28300856
[TBL] [Abstract][Full Text] [Related]
2. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay.
Kircik LH
J Drugs Dermatol; 2014 May; 13(5):582-5. PubMed ID: 24809882
[TBL] [Abstract][Full Text] [Related]
3. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
[TBL] [Abstract][Full Text] [Related]
4. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
[TBL] [Abstract][Full Text] [Related]
6. Specific dermatological benefits associated with quantities of lotion transferred to the skin.
Farage MA; Esquerra J; Cheng R; Carpenter S; Bunasky K; Gutshall D; Lawrence A; Messerschmidt A
J Cosmet Dermatol; 2018 Oct; 17(5):900-910. PubMed ID: 29094461
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis.
Yawalkar SJ; Schwerzmann L
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1163-6. PubMed ID: 1757610
[TBL] [Abstract][Full Text] [Related]
8. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
Breneman D; Fleischer AB; Kaplan D; Lebwohl M; Miller B; Pariser D; Rist T; Swinyer L; Liu Y; Foley V
J Drugs Dermatol; 2005; 4(3):330-6. PubMed ID: 15898289
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
10. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Tanghetti EA; Stein Gold L; Del Rosso JQ; Lin T; Angel A; Pillai R
J Dermatolog Treat; 2021 Jun; 32(4):391-398. PubMed ID: 31522563
[TBL] [Abstract][Full Text] [Related]
11. Transepidermal water loss (TEWL) and corneometry with hydrogel vehicle in the treatment of atopic dermatitis: a randomized, investigator-blind pilot study.
Kircik LH
J Drugs Dermatol; 2012 Feb; 11(2):180-4. PubMed ID: 22270199
[TBL] [Abstract][Full Text] [Related]
12. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
[TBL] [Abstract][Full Text] [Related]
14. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses.
Kantor I; Cook PR; Cullen SI; Willis I; Gibson JR; Stanfield JW
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1184-6. PubMed ID: 1757615
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
16. Effect of a new moisturizing lotion on immediate and cumulative skin hydration: Two randomized, intra-individual, vehicle- and comparator-controlled studies.
Nogueira A; Sidou F; Brocard S
J Dermatolog Treat; 2011 Aug; 22(4):221-5. PubMed ID: 20687845
[TBL] [Abstract][Full Text] [Related]
17. Anti-Pruritic Efficacy of Itch Relief Lotion and Cream in Patients With Atopic History: Comparison With Hydrocortisone Cream.
Zirwas MJ; Barkovic S
J Drugs Dermatol; 2017 Mar; 16(3):243-247. PubMed ID: 28301620
[TBL] [Abstract][Full Text] [Related]
18. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.
Herz G; Blum G; Yawalkar S
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1166-9. PubMed ID: 1757611
[TBL] [Abstract][Full Text] [Related]
19. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
[TBL] [Abstract][Full Text] [Related]
20. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
